CJC-1295 vs Ipamorelin: Research Peptide Comparison

CJC-1295 and ipamorelin are frequently mentioned together in growth hormone secretagogue research, which is why they are often compared. This article sets out how they differ — in receptor family, structure and the research areas each appears in — and how each is handled as laboratory material. It is a comparison rather than a pair of profiles; for full background, follow the links to each compound’s guide.

Everything here is factual and educational. It is not guidance for the use of any material in humans or animals, and it makes no claim about safety, performance or outcomes. For the wider class, see Growth Hormone Secretagogue Research Peptides.

The table below summarises the factual points of difference.

The key difference is the receptor route. CJC-1295 (no DAC) is a stabilised analogue of growth-hormone-releasing hormone and acts at the GHRH receptor; ipamorelin is a pentapeptide growth-hormone-releasing peptide that acts at the ghrelin receptor, also called the growth hormone secretagogue receptor. Because the two engage different receptors on the same broad pathway, they are often studied as a pair. These are descriptions of receptor activity studied in the laboratory, not statements about any effect. The detail is in the CJC-1295 research overview and the ipamorelin research overview.

The two are structurally quite different. CJC-1295 (no DAC) is built on the GHRH(1-29) sequence with stabilising modifications, while ipamorelin is a short five-residue peptide. That contrast — a modified hormone fragment versus a compact synthetic pentapeptide — reflects their different families. For background on how such sequences are described, see Understanding Peptide Sequence Notation.

Both appear in growth hormone secretagogue research, and the descriptions here summarise where each is studied rather than any established result. CJC-1295 features in GHRH-receptor work; ipamorelin features in ghrelin-receptor work, where its reported selectivity makes it a useful probe. These are areas of published study, not recommended uses.

Both are supplied as lyophilised peptides and handled the same way: confirm the material against its specification on receipt, keep it in the stated storage conditions, and maintain clear records. See CJC-1295 Storage & Handling, Ipamorelin Storage & Handling and the general Peptide Storage Guidelines.

The choice follows the receptor under study: GHRH-receptor work points toward CJC-1295, ghrelin-receptor work toward ipamorelin, and work comparing the two routes uses both. Neither framing implies one is superior. Both sit within the class covered in Growth Hormone Secretagogue Research Peptides.

Both peptides are available in the catalogue with full specifications and storage information: CJC-1295 (no DAC) and Ipamorelin. The complete range is in the research catalogue, and our approach to material consistency is on the Quality page.

For laboratory research use only. Not for human or animal consumption. The material on this page is educational and factual: it compares how two research compounds are described in published study and handled in the laboratory. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance or outcomes. Where a product specification is provided with a material, that document is the definitive reference and takes precedence over any general information given here.